Zoetis Inc. (ZTS) Earnings

Zoetis Inc.

ZTS · NYSE

Jun 2026upcoming

Next quarter

Consensus is $1.84 EPS for Jun 2026 across 8 estimates, ranging $1.77 to $1.89.

ZTS Mar 2026

Reported May 7, 2026

Miss 4.97%

EPS estimate: $1.61
EPS actual: $1.53
Revenue estimate: —
Revenue actual: —
1-day move: -5.13%

Call highlights have not been generated for this quarter.

Symbol: ZTS
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, robust post marketing surveillance (PV), and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.

Key Issues

Bullish view

Companion-animal products are a central focus ahead of the second-quarter report, and continued demand could support earnings growth.

Bearish view

The evidence identifies U.S. competition as a counterweight, potentially limiting growth even if companion-animal products remain a strategic strength.

Analyst Consensus

See all

Hold

16 analysts

$74

Current

—

Low

$97

Average

—

High

Average target implies +30.92% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Royalty Pharma plc Class A Ordinary Shares